Retinal Vein Occlusion Market Report 2026

Retinal Vein Occlusion Market Overview

• Retinal Vein Occlusion market size has reached to $17.03 billion in 2025 • Expected to grow to $28.23 billion in 2030 at a compound annual growth rate (CAGR) of 10.8% • Growth Driver: Rising Prevalence Of Eye Disorders Fuels Growth In The Ocular Drug Delivery Market • Market Trend: Pioneering Innovations In The Retinal Vein Occlusion Market To Gain Competitive Advantage • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Retinal Vein Occlusion Market?

Retinal vein occlusion (RVO) is a medical condition that occurs when a blockage or obstruction in the veins carries blood away from the retina, the light-sensitive tissue at the back of the eye. (RVO) can be avoided by preventing other blood vessel illnesses that raise the risk of RVO. This can be controlled by consuming a low-fat diet, regular exercise and maintaining a healthy weight. The main types of retinal vein occlusion are branch retinal artery occlusion and central retinal vein occlusion. Branch retinal artery occlusion refers to a condition characterized by decreased arterial blood flow to a branch of the central retinal artery, leading to ischemic damage in the affected area of the retina, which is treated with ocular hypotensive drugs such as topical timolol or IV or oral acetazolamide. These conditions are categorized into non-ischemic and ischemic types, which are diagnosed by optical coherence tomography, fundoscopic examination and fluorescein angiography. The treatment approach includes antivascular endothelial growth factor, corticosteroid drugs and laser retinal photocoagulation provided by end users such as hospitals and clinics, research and academic centers and others.

What Is The Retinal Vein Occlusion Market Growth Forecast?

The retinal vein occlusion market size is expected to see rapid growth in the next few years. It will grow to $28.23 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to increasing aging population, rising demand for minimally invasive treatments, expansion of personalized ophthalmic care, growing investments in retinal disease research, increasing adoption of combination therapy approaches. Major trends in the forecast period include increasing adoption of anti-vegf therapies, rising use of advanced retinal imaging diagnostics, growing focus on early detection of vascular disorders, expansion of outpatient ophthalmic treatment models, enhanced monitoring of disease progression.

Global Retinal Vein Occlusion Market Segmentation

1) By Type: Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion 2) By Condition: Non-Ischemic, Ischemic 3) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography 4) By Treatment: Antivascular Endothelial Growth Factor, Corticosteroid Drugs, Laser Retinal Photocoagulation 5) By End User: Hospitals And Clinics, Research And Academics Centers, Other End-Users Subsegments: 1) By Branch Retinal Vein Occlusion: Non-Ischemic Branch Retinal Vein Occlusion, Ischemic Branch Retinal Vein Occlusion 2) By Central Retinal Vein Occlusion: Non-ischemic Central Retinal Vein Occlusion, Ischemic Central Retinal Vein Occlusion

What Is The Driver Of The Retinal Vein Occlusion Market?

An increase in the prevalence of eye disorders is expected to propel the growth of the ocular drug delivery market going forward. Eye disorders refer to a wide range of conditions that affect the eyes, vision, or the structures surrounding the eyes. The increased incidence of renal vein occlusion drives growth in the renal vein occlusion market, fostering demand for innovative diagnostics and treatments to address this condition. For instance, in October 2023, according to the Royal National Institute of Blind People (RNIB), a UK-based sight loss charity, eye care outpatient appointments in the UK reached over eight million in 2021/22, the highest for any specialty, and the number of people with sight loss, currently exceeding two million, is expected to double to over four million by 2050. Therefore, the increasing prevalence of eye disorders will drive the retinal vein occlusion industry.

Key Players In The Global Retinal Vein Occlusion Market

Major companies operating in the retinal vein occlusion market are Pfizer Inc., Roche Holding AG, Merck And Co Inc., Bayer AG, Novartis AG, Allergan PLC, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Carl Zeiss AG, Santen Pharmaceutical Co Ltd, Lumenis Ltd, Coherus Biosciences Inc., Genentech Inc., Topcon Corporation, Nidek Co Ltd, IRIDEX Corporation, Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Ellex Medical Lasers Ltd, Adverum Biotechnologies Inc., Outlook Therapeutics Inc., Annexin Pharmaceuticals AB, Ingenia Therapeutics Inc., Samsung Bioepis

Global Retinal Vein Occlusion Market Trends and Insights

Major companies operating in the retinal vein occlusion market are focusing on developing innovative advancements such as next-generation pattern-scanning laser platforms to enhance treatment precision, efficiency, and patient-specific disease management. Next-generation pattern-scanning laser platforms refer to advanced ophthalmic laser systems that integrate high-speed pattern delivery, tissue-sparing energy modulation, and multimodal laser capabilities to optimize therapeutic outcomes for retinal vascular disorders. For instance, in April 2023, Iridex Corporation, a US-based ophthalmic medical technology company, launched the next-generation Iridex PASCAL. The brand-new platform offers a cutting-edge technology package that combines rapid and accurate pattern scanning abilities, endpoint management technology, a pattern scanning laser trabeculoplasty and micropulse technology in a more compact, ergonomically designed integrated laser platform to provide individualized care to patients with retinal disease.

What Are Latest Mergers And Acquisitions In The Retinal Vein Occlusion Market?

In October 2025, Novartis Pharma Services AG, a Switzerland-based provider of pharmaceutical research, development, and manufacturing, signed an exclusive 5-year distribution agreement with CMS Vision International Management Ltd. for two eye-disease drugs. This deal aims to leverage Kangzhi’s strong ophthalmology presence and sales network to expand access and commercial reach in China. Novartis Pharma Services AG is based in Switzerland and develops and supplies innovative medicines. CMS Vision International Management Ltd. (Kangzhi) is a China-based specialist in ophthalmic drugs and devices, marketing products for retina disease, glaucoma, and ocular fatigue.

Regional Outlook

North America was the largest region in the retinal vein occlusion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Retinal Vein Occlusion Market?

The retinal vein occlusion market consists of revenues earned by entities by providing services such as surgery and pan retinal photocoagulation. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinal vein occlusion market also includes sales of ranibizumab and aflibercept. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Retinal Vein Occlusion Market Report 2026?

The retinal vein occlusion market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the retinal vein occlusion industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.